Literature DB >> 1920366

Immunohistochemical studies show truncated dystrophins in the myotubes of three fetuses at risk for Duchenne muscular dystrophy.

I B Ginjaar1, E Bakker, M M van Paassen, J T den Dunnen, A Wessels, E E Zubrzycka-Gaarn, A F Moorman, G J van Ommen.   

Abstract

We have performed immunohistochemical studies on muscle tissue of three 12 week old fetuses at risk for DMD, using antisera directed against regions located NH2-proximally and centrally in the rod shaped spectrin-like domain and against the COOH-terminus of dystrophin. All three fetuses had a family history of DMD. Truncated dystrophins were identified in all three cases by a positive reaction with the NH2-proximal antibody, different reactions with the central antibody, and a negative reaction with the COOH-terminal antibody. These data indicate that a panel of antibodies would, in principle, permit 'immunological' mapping of dystrophin mutations. This is diagnostically important in the 35% of families where no mutation is detectable at the DNA level. Secondly, by using this mapping technique it may also become possible to identify the at risk haplotype when DNA analysis is not informative. This may be of great value in DMD carrier detection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920366      PMCID: PMC1016976          DOI: 10.1136/jmg.28.8.505

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  34 in total

1.  Mosaic expression of dystrophin in symptomatic carriers of Duchenne's muscular dystrophy.

Authors:  K Arahata; T Ishihara; K Kamakura; T Tsukahara; S Ishiura; C Baba; T Matsumoto; I Nonaka; H Sugita
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245

2.  A deletion hot spot in the Duchenne muscular dystrophy gene.

Authors:  M C Wapenaar; T Kievits; K A Hart; S Abbs; L A Blonden; J T den Dunnen; P M Grootscholten; E Bakker; C Verellen-Dumoulin; M Bobrow
Journal:  Genomics       Date:  1988-02       Impact factor: 5.736

3.  Development of additional RFLP probes near the locus for Duchenne muscular dystrophy by cosmid cloning of the DXS84 (754) locus.

Authors:  M H Hofker; G J van Ommen; E Bakker; M Burmeister; P L Pearson
Journal:  Hum Genet       Date:  1986-11       Impact factor: 4.132

4.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

5.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy.

Authors:  S B Malhotra; K A Hart; H J Klamut; N S Thomas; S E Bodrug; A H Burghes; M Bobrow; P S Harper; M W Thompson; P N Ray
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

6.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

7.  Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies.

Authors:  L L Baumbach; J S Chamberlain; P A Ward; N J Farwell; C T Caskey
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

8.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

9.  Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene.

Authors:  E F Gillard; J S Chamberlain; E G Murphy; C L Duff; B Smith; A H Burghes; M W Thompson; J Sutherland; I Oss; S E Bodrug
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

10.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

View more
  3 in total

1.  Monoclonal antibodies for dystrophin analysis. Epitope mapping and improved binding to SDS-treated muscle sections.

Authors:  T M Nguyen; I B Ginjaar; G J van Ommen; G E Morris
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

Review 2.  The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy.

Authors:  Jamie L Marshall; Yukwah Kwok; Brian J McMorran; Linda G Baum; Rachelle H Crosbie-Watson
Journal:  FEBS J       Date:  2013-05-13       Impact factor: 5.542

3.  The use of monoclonal antibodies in diagnostic tests for Becker and Duchenne muscular dystrophy.

Authors:  R Gold; W Kress; H Reichmann; C R Müller
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.